Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Equity Ratio (2019 - 2025)

BridgeBio Pharma's Equity Ratio history spans 7 years, with the latest figure at 2.23 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 39.61% year-over-year to 2.23; the TTM value through Dec 2025 reached 2.23, down 39.61%, while the annual FY2025 figure was 2.23, 39.61% down from the prior year.
  • Equity Ratio for Q4 2025 was 2.23 at BridgeBio Pharma, down from 1.93 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.36 in Q1 2021 and bottomed at 2.68 in Q2 2023.
  • The 5-year median for Equity Ratio is 1.62 (2024), against an average of 1.56.
  • The largest annual shift saw Equity Ratio crashed 666.85% in 2021 before it surged 49.19% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.86 in 2021, then crashed by 133.12% to 2.0 in 2022, then decreased by 23.17% to 2.46 in 2023, then surged by 35.04% to 1.6 in 2024, then crashed by 39.61% to 2.23 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Equity Ratio are 2.23 (Q4 2025), 1.93 (Q3 2025), and 1.65 (Q2 2025).